Wealth Advisory Solutions’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-28,577
Closed -$1.59M 147
2025
Q3
$1.59M Sell
28,577
-14,300
-33% -$837K 0.38% 60
2025
Q2
$2.96M Buy
42,877
+340
+0.8% +$23.1K 0.75% 38
2025
Q1
$2.95M Buy
42,537
+3,103
+8% +$256K 0.78% 40
2024
Q4
$3.39M Buy
39,434
+12,629
+47% +$1.37M 0.95% 28
2024
Q3
$3.19M Sell
26,805
-3,020
-10% -$403K 0.88% 32
2024
Q2
$4.26M Sell
29,825
-16,230
-35% -$2.15M 1.15% 27
2024
Q1
$5.91M Buy
46,055
+489
+1% +$58.2K 1.53% 17
2023
Q4
$4.71M Sell
45,566
-44,290
-49% -$4.38M 1.65% 21
2023
Q3
$8.74M Buy
89,856
+45,328
+102% +$3.99M 1.71% 18
2023
Q2
$3.6M Sell
44,528
-304
-0.7% -$24.8K 0.96% 29
2023
Q1
$3.57M Sell
44,832
-18,772
-30% -$1.33M 0.95% 31
2022
Q4
$4.3M Sell
63,604
-68
-0.1% -$3.99K 1.16% 21
2022
Q3
$3.17M Buy
+63,672
New +$3.41M 0.88% 38

Other funds holding NVO

Wealth Advisory Solutions's NVO Position: Q4 2025 in Review

Wealth Advisory Solutions sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 28,577 shares — an estimated $1.59M sold.

Wealth Advisory Solutions first reported a position in NVO in Q3 2022 and held it in 13 quarters. The position peaked at $8.74M in Q3 2023. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Wealth Advisory Solutions reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Wealth Advisory Solutions sold 28,577 Novo Nordisk shares in Q4 2025, an estimated $1.59M.
  • Wealth Advisory Solutions first reported a position in Novo Nordisk in Q3 2022 and held it in 13 quarters.
  • Wealth Advisory Solutions's Novo Nordisk position peaked at $8.74M in Q3 2023.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Wealth Advisory Solutions's 13F filing for Q4 2025, filed 16 Jan 2026.